Amicus Therapeutics, Inc. (FOLD): Small-Cap Biotech with Large Hedge Fund Ownership

Amicus Therapeutics, Inc. (NASDAQ:FOLD)'s lead drug candidate is migalastat, which targets Fabry disease.

Keep Reading →